What is the preferred treatment between Breztri (budesonide, glycopyrrolate, and formoterol) and Trelegy (fluticasone furoate, umeclidinium, and vilanterol) for a patient with chronic obstructive pulmonary disease (COPD) and a history of exacerbations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Breztri vs Trelegy for COPD with Exacerbation History

Both Breztri (budesonide/glycopyrrolate/formoterol) and Trelegy (fluticasone furoate/umeclidinium/vilanterol) are equally effective triple therapy options for COPD patients with exacerbation history, with no clinically meaningful differences in mortality, exacerbation reduction, lung function, or safety outcomes. 1, 2

Evidence Supporting Equivalence

The most recent and comprehensive meta-analysis directly comparing these agents found no significant differences across critical outcomes 1:

  • Exacerbation rates: No significant difference (p > 0.05) between BDP/FOR/GLY, BUD/GLY/FOR (Breztri), and FF/UMEC/VI (Trelegy) 1
  • Lung function (trough FEV1): Comparable improvements across all triple FDCs 1, 2
  • Symptom control (TDI, SGRQ): No significant differences in dyspnea or quality of life measures 1, 2
  • Safety profile: Similar rates of serious adverse events, cardiovascular events, pneumonia, and all-cause mortality 1, 2

A 2021 network meta-analysis of 37,741 patients over 52 weeks confirmed that BUD/GLY/FOR (Breztri) showed comparable efficacy to FF/UMEC/VI (Trelegy) across all measured outcomes including exacerbations, lung function, symptoms, and health-related quality of life 2.

Guideline-Based Indications for Triple Therapy

Both medications are appropriate for patients meeting these criteria 3, 4, 5:

  • FEV1 <50% predicted with history of ≥2 moderate exacerbations or ≥1 severe exacerbation requiring hospitalization in the previous year 6
  • Persistent symptoms or exacerbations despite optimal dual bronchodilator therapy (LAMA/LABA) 3, 5
  • GOLD Group D patients (high symptom burden + high exacerbation risk) 3, 5

The Canadian Thoracic Society strongly recommends LAMA/LABA/ICS triple combination therapy over dual therapy for patients with high exacerbation risk, moderate to high symptom burden, and impaired lung function, based on moderate certainty evidence showing greater reduction in mortality 4, 5.

Practical Considerations for Selection

Dosing Frequency

  • Breztri: Twice-daily administration (BID) 1
  • Trelegy: Once-daily administration (QD) 7, 1, 8

Single-inhaler triple therapy may improve adherence compared to multiple inhalers, and once-daily dosing with a simple device may further increase adherence 5, 8.

ICS Dose and Mortality Benefit

The ETHOS study demonstrated that the moderate dose of budesonide (320 μg in Breztri) showed a mortality benefit 5. Higher ICS doses are not typically necessary for optimal benefit in COPD 5.

Pneumonia Risk

Both regimens carry similar pneumonia risk 1, 2. The incidence of pneumonia is slightly higher with ICS-containing regimens, but the benefit-risk ratio favors triple therapy in appropriate patients, with a number needed to treat of 4 to prevent one moderate-to-severe exacerbation versus a number needed to harm of 33 for pneumonia 5.

Monitor patients with these risk factors more closely 5:

  • Current smokers
  • Age ≥55 years
  • Prior exacerbations or pneumonia
  • BMI <25 kg/m²
  • Severe airflow limitation

Clinical Decision Algorithm

Choose either medication based on:

  1. Patient preference for dosing frequency: Once-daily (Trelegy) versus twice-daily (Breztri) 1, 8
  2. Insurance formulary coverage: Select the option with better coverage/lower cost
  3. Prior ICS exposure: If patient has tolerated budesonide previously, Breztri may be preferred; if fluticasone furoate, then Trelegy 1, 2

Do not switch between these agents once stable on either medication, as they provide equivalent outcomes and switching introduces unnecessary risk of technique errors and non-adherence 1, 2.

Common Pitfalls to Avoid

  • Do not add a second LAMA to either triple therapy regimen—both already contain a LAMA component (glycopyrrolate in Breztri, umeclidinium in Trelegy) 4
  • Do not step down from triple therapy during or immediately after an exacerbation, as ICS withdrawal increases recurrent exacerbation risk, particularly in patients with eosinophils ≥300 cells/μL 4
  • Do not use theophylline as add-on therapy to triple therapy due to low certainty of benefit and high risk of adverse events and drug interactions 5
  • Monitor for oral candidiasis, hoarseness, and dysphonia with both ICS-containing regimens 5

When Triple Therapy Fails

If patients continue to exacerbate despite triple therapy, consider 3, 4:

  • Roflumilast: For FEV1 <50% predicted with chronic bronchitis phenotype and ≥1 hospitalization for exacerbation in the previous year 3
  • Macrolide maintenance therapy (azithromycin): For former smokers with frequent exacerbations, considering QT prolongation risk and bacterial resistance 3, 4
  • Pulmonary rehabilitation: Schedule within 3 weeks after any exacerbation to reduce readmissions 4

References

4
Guideline

COPD Exacerbation Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5
Guideline

Evidence for Triple Therapy in COPD Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What considerations should be taken when switching a patient with Chronic Obstructive Pulmonary Disease (COPD) from Trelegy (fluticasone furoate, umeclidinium, and vilanterol) to Breztri (budesonide, glycopyrrolate, and formoterol)?
What recommendations are appropriate for a patient taking aspirin 81 mg daily, atorvastatin 80 mg daily, clopidogrel, furosemide 40 mg daily, potassium chloride extended‑release 10 mEq daily, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) daily, and Ventolin HFA (albuterol) as needed, who is anxious and experiences daily shortness of breath, especially midday and evening with increased exertion?
Can an elderly patient take Trelegy Ellipta (fluticasone furoate + umeclidinium + vilanterol) and prednisone together?
Is it safe to use both Anoro (umeclidinium/vilanterol) and Symbicort (budesonide/formoterol) concurrently?
Is Pulmicort (budesonide) more effective than Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) for treating asthma or Chronic Obstructive Pulmonary Disease (COPD)?
What type of computed tomography (CT) scan is needed for an older adult with a history of osteoporosis and scoliosis after a fall and head injury?
Is it necessary to monitor electrolyte levels in a patient with clinical rabies?
Is Vantin (cefepime) suitable for a patient with a urinary tract infection (UTI), diabetes, and impaired circulation?
What is the appropriate dosage of Cefpodoxime for an adult or adolescent patient with a bacterial infection and no known allergies to cephalosporins?
What potential interactions should be considered in a patient taking Pramipexole (Sifrol), Venlafaxine (Effexor), Agomelatine, Pantoprazole, and Salbutamol (Ventolin) as needed, who is requesting a rescript for restless legs syndrome?
How do I differentiate between myopericarditis and pericarditis in an adult patient with chest pain and elevated troponin levels, possibly with a history of cardiac issues or recent viral infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.